Company: PRTA
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001559053-25-000044
Chunk: 22

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 22
---
65 s.

The following table summarizes share-based compensation expense for the periods presented (in thousands):

                                              Three Months Ended                                       Nine Months Ended                          
                                              September 30,                                            September 30,                              
                                              2025                               2024                  2025                                       
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Research and development                    $                       2,471      $          5,128      $                      11,990      16,217  
  General and administrative                                          4,728                 5,892                             16,495      19,227  
  Restructuring costs (1)                     —                                  —                                             2,081              
  Total share-based compensation expense      $                       7,199      $         11,020      $                      30,566      35,444  

________________

(1) Restructuring costs for the nine months ended September 30, 2025 includes$ 2.1

The Company recognized tax benefits from share-based awards of $ 2.0 6.3 no

The fair value of the options granted to employees and non-employee directors during the nine months ended September 30, 2025 and 2024 was estimated as of the grant date using the Black-Scholes option-pricing model using the key assumptions listed in the following table. There were no stock options granted during the three months ended September 30, 2025 and 2024, thus no key assumptions are shown in the table below.

                                              Nine Months Ended                                     
                                                  September 30,                                     
                                                           2025                    2024             
 ────────────────────────────────────────────────────────────────────────────────────────────────────
  Expected term (in years)                                 4.78       5.76         4.60       5.56  
  Expected volatility                                     76.5%      79.0%         74.5      78.6%  
  Risk-free interest rate                                  3.8%       4.4%          3.8       4.7%  
  Expected dividend yield                                    —%                      —%             
  Weighted average grant date fair value                 $ 9.49                 $ 19.21             

The fair value of employee stock options is amortized on a straight-line basis over the requisite service period for each award. Each of the inputs discussed above is subjective and generally